TIAA CREF Investment Management LLC lowered its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 5.6% during the first quarter, Holdings Channel reports. The firm owned 230,338 shares of the biopharmaceutical company’s stock after selling 13,701 shares during the period. TIAA CREF Investment Management LLC’s holdings in Inovio Pharmaceuticals were worth $1,525,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. American International Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock worth $270,000 after buying an additional 2,695 shares during the period. Wells Fargo & Company MN boosted its position in shares of Inovio Pharmaceuticals by 28.9% in the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock worth $825,000 after buying an additional 27,898 shares during the period. Vident Investment Advisory LLC boosted its position in shares of Inovio Pharmaceuticals by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 127,375 shares of the biopharmaceutical company’s stock worth $843,000 after buying an additional 21,228 shares during the period. Teachers Advisors LLC boosted its position in shares of Inovio Pharmaceuticals by 2.3% in the first quarter. Teachers Advisors LLC now owns 151,775 shares of the biopharmaceutical company’s stock worth $1,005,000 after buying an additional 3,411 shares during the period. Finally, Stoneridge Investment Partners LLC boosted its position in shares of Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock worth $1,684,000 after buying an additional 2,073 shares during the period. Hedge funds and other institutional investors own 22.92% of the company’s stock.

Inovio Pharmaceuticals, Inc. (INO) traded up 1.28% during trading on Friday, hitting $5.56. The stock had a trading volume of 1,077,056 shares. The firm’s market capitalization is $501.66 million. The stock has a 50 day moving average of $6.81 and a 200 day moving average of $6.81. Inovio Pharmaceuticals, Inc. has a one year low of $5.32 and a one year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The company had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The firm’s revenue for the quarter was up 229.2% compared to the same quarter last year. Equities research analysts expect that Inovio Pharmaceuticals, Inc. will post ($0.93) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Inovio Pharmaceuticals, Inc. (INO) Stake Reduced by TIAA CREF Investment Management LLC” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-stake-reduced-by-tiaa-cref-investment-management-llc/1477945.html.

Several equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 15th. Stifel Nicolaus reiterated a “buy” rating and set a $11.00 price objective on shares of Inovio Pharmaceuticals in a report on Tuesday, April 25th. BNP Paribas reiterated a “neutral” rating and set a $39.00 price objective on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 7th. Finally, Aegis lifted their price objective on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, May 25th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $20.78.

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now owns 740,956 shares in the company, valued at $5,927,648. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.60% of the stock is owned by corporate insiders.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.